



of incorporation)

Identification No.)

105 Lincoln Avenue  
Buena, New Jersey 08310  
(Address of principal executive offices and zip code)

Registrant's telephone number, including area code: (856) 697-1441

---

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 2.02. Results of Operations and Financial Condition.**

On October 22, 2015, IGI Laboratories, Inc. (the “**Company**”) issued a press release announcing the Company’s earnings for the third quarter ended September 30, 2015 and certain other information. A copy of the press release is attached hereto as Exhibit 99.1.

The Company will conduct a conference call to review its financial results on October 22, 2015, at 4:15 p.m., Eastern Time.

The information, including Exhibit 99.1, in this Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section. The information in this Form 8-K shall not be incorporated by reference into any filing under the Securities Act of 1933, except as shall otherwise be expressly set forth by specific reference in such filing.

**Item 8.01 Other Events.**

On October 22, 2015, the Company issued a press release announcing (1) that the Company will be changing its name to “Teligent, Inc.” effective as of October 23, 2015, at 5:00 P.M. Eastern Daylight Time and (2) that the Company’s common stock, par value \$0.01 per share, which was previously approved for listing on The NASDAQ Global Select Market, will be quoted under the trading symbol “TLGT” as of the first day of trading on such exchange on Monday, October 26, 2015. A copy of the press release is attached hereto as Exhibit 99.2, and incorporated herein by reference.

Neither the filing of the press release as an exhibit to this Current Report on Form 8-K nor the inclusion in the press release of a reference to the Company’s internet address shall, under any circumstances, be deemed to incorporate the information available at the Company’s internet address into this Current Report on Form 8-K. The information available at the Company’s internet address is not part of this Current Report on Form 8-K or any other report filed by it with the Securities and Exchange Commission.

**Item 9.01 Financial Statements and Exhibits.**

(d) The following exhibits are filed with this Report:

**Exhibit No. Description**

99.1 Press release of IGI Laboratories, Inc., dated October 22, 2015.

99.2 Press release of IGI Laboratories, Inc., dated October 22, 2015.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**IGI LABORATORIES, INC.**

By: /s/ Jenniffer Collins  
Name: Jenniffer Collins  
Title: Chief Financial Officer

Date: October 22, 2015